Jany S - Search Results

1

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice.

Veit S, Jany S, Fux R, Sutter G, Volz A. Veit S, et al. Among authors: jany s. Viruses. 2018 Dec 16;10(12):718. doi: 10.3390/v10120718. Viruses. 2018. PMID: 30558354 Free PMC article.

2

Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.

Volz A, Langenmayer M, Jany S, Kalinke U, Sutter G. Volz A, et al. Among authors: jany s. J Virol. 2014 Sep;88(18):10946-57. doi: 10.1128/JVI.00945-14. Epub 2014 Jul 9. J Virol. 2014. PMID: 25008931 Free PMC article.

3

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.

Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, Sutter G. Volz A, et al. Among authors: jany s. J Virol. 2015 Aug;89(16):8651-6. doi: 10.1128/JVI.00614-15. Epub 2015 May 27. J Virol. 2015. PMID: 26018172 Free PMC article.

4

Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.

Volz A, Lim S, Kaserer M, Lülf A, Marr L, Jany S, Deeg CA, Pijlman GP, Koraka P, Osterhaus AD, Martina BE, Sutter G. Volz A, et al. Among authors: jany s. Vaccine. 2016 Apr 7;34(16):1915-26. doi: 10.1016/j.vaccine.2016.02.042. Epub 2016 Mar 2. Vaccine. 2016. PMID: 26939903

5

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.

Volz A, Jany S, Freudenstein A, Lantermann M, Ludwig H, Sutter G. Volz A, et al. Among authors: jany s. Viruses. 2018 Jan 4;10(1):21. doi: 10.3390/v10010021. Viruses. 2018. PMID: 29300297 Free PMC article.

6

A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice.

Kalodimou G, Veit S, Jany S, Kalinke U, Broder CC, Sutter G, Volz A. Kalodimou G, et al. Among authors: jany s. Viruses. 2019 Dec 24;12(1):26. doi: 10.3390/v12010026. Viruses. 2019. PMID: 31878180 Free PMC article.

7

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.

Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, Limpinsel L, Okba NMA, Bošnjak B, Sandrock I, Odak I, Halwe S, Sauerhering L, Brosinski K, Liangliang N, Duell E, Jany S, Freudenstein A, Schmidt J, Werner A, Gellhorn Serra M, Klüver M, Guggemos W, Seilmaier M, Wendtner CM, Förster R, Haagmans BL, Becker S, Sutter G, Volz A. Tscherne A, et al. Among authors: jany s. Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):e2026207118. doi: 10.1073/pnas.2026207118. Proc Natl Acad Sci U S A. 2021. PMID: 34162739 Free PMC article.

8

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein.

Kupke A, Volz A, Dietzel E, Freudenstein A, Schmidt J, Shams-Eldin H, Jany S, Sauerhering L, Krähling V, Gellhorn Serra M, Herden C, Eickmann M, Becker S, Sutter G. Kupke A, et al. Among authors: jany s. Vaccines (Basel). 2022 Mar 29;10(4):533. doi: 10.3390/vaccines10040533. Vaccines (Basel). 2022. PMID: 35455282 Free PMC article.

9

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.

Meyer Zu Natrup C, Tscherne A, Dahlke C, Ciurkiewicz M, Shin DL, Fathi A, Rohde C, Kalodimou G, Halwe S, Limpinsel L, Schwarz JH, Klug M, Esen M, Schneiderhan-Marra N, Dulovic A, Kupke A, Brosinski K, Clever S, Schünemann LM, Beythien G, Armando F, Mayer L, Weskamm ML, Jany S, Freudenstein A, Tuchel T, Baumgärtner W, Kremsner P, Fendel R, Addo MM, Becker S, Sutter G, Volz A. Meyer Zu Natrup C, et al. Among authors: jany s. J Clin Invest. 2022 Dec 15;132(24):e159895. doi: 10.1172/JCI159895. J Clin Invest. 2022. PMID: 36301637 Free PMC article.

10

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.

Kalodimou G, Jany S, Freudenstein A, Schwarz JH, Limpinsel L, Rohde C, Kupke A, Becker S, Volz A, Tscherne A, Sutter G. Kalodimou G, et al. Among authors: jany s. Viruses. 2023 May 17;15(5):1180. doi: 10.3390/v15051180. Viruses. 2023. PMID: 37243266 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page